Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q86X76

UPID:
NIT1_HUMAN

ALTERNATIVE NAMES:
Nitrilase homolog 1

ALTERNATIVE UPACC:
Q86X76; B1AQP3; D3DVF4; O76091

BACKGROUND:
The protein Deaminated glutathione amidase, known alternatively as Nitrilase homolog 1, is pivotal in the detoxification process of deaminated glutathione through its enzymatic activity. This process is vital for maintaining cellular health and preventing the accumulation of harmful substances. Additionally, the protein's role extends to regulating cell growth and apoptosis, where its absence has been associated with increased cell proliferation, resistance to stress from DNA damage, and elevated tumor incidence.

THERAPEUTIC SIGNIFICANCE:
The exploration of Deaminated glutathione amidase's functions offers promising avenues for therapeutic intervention. Given its dual role in tumor suppression and regulation of apoptosis, targeting this protein could enhance treatment efficacy against various cancers. Moreover, its impact on T-cell regulation presents an opportunity for developing novel immunotherapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.